Scientific method relies on a constant scrutiny of every theory, technology, medication, or development. If it consistently proves its validity, its effectiveness, then is established, and it becomes legitimate.
Our technology has been studied in various national and international laboratories, where its effectiveness has been repeatedly confirmed. This has been mainly driven by the SarsCoV2 pandemic and the interest of several countries in having products with this active ingredient.
Below are some of the initial institutions that validated and endorsed the effectiveness of our Nano-Bio-Technology, along with a list of studies confirming the efficacy of the technology used in Éviter and Eion products.

Instituto Nacional de Enfermedades Respiratorias (National Institute of Respiratory Diseases):
The INER houses Mexico's most important virology and microbiology laboratory, responsible, among other things, for identifying the A-H1N1 virus strain during the 2009 pandemic, which led to the development of the vaccine. In this same laboratory, the inhibitory effect of the nano bio molecule, the active ingredient in Éviter, on the infection of the influenza A-H1N1 virus in MDCK cells was demonstrated.
Instituto Politécnico Nacional (National Polytechnic Institute):
In its immunochemistry laboratory, an antimycobacterial assay was conducted, concluding with a positive result of 99% inhibition of both tuberculous and non-tuberculous mycobacteria that were tested.
Universidad Autónoma de Nuevo León (Autonomous University of Nuevo León):


Hospital 20 de Noviembre:
In its Genomic Medicine division, it was demonstrated that human-origin DNA, which came into contact with NanoBioMolecule suspension at different times and concentrations, did not undergo any degradation. This confirms that the NanoBioTechnology used in Éviter® is completely safe to use.
Some of the studies we have conducted include:
1. Classification of ingredients with CAS numbers from the American Chemical Society.
2. National Institute of Medical Sciences and Nutrition Salvador Zubirán. Antimicrobial activity of Éviter.
3. UANL Autonomous University of Nuevo León. Biodegradability.
4. UANL Autonomous University of Nuevo León. Non-irritability.
5. LabTox Laboratory. Department of Biology and Reproductive Toxicology at the Institute of Sciences (ICUAP). Acute dermal protocol.
6. Industrial Microbiological Laboratory MICROMEX, SA de CV. Pathogen analysis on hands and nails.
7. Lloydmex Laboratories. Microbial effectiveness in the food industry.
8. UANL Autonomous University of Nuevo León. Antimicrobial sanitizing activity.
9. CEICALab. Microbial challenge Escherichia coli, Staphylococcus aureus.
10. CEICALab. Germicidal Report.
11. UANL Autonomous University of Nuevo León. Antimicrobial activity in toothpaste.
12. UANL Autonomous University of Nuevo León. Antimicrobial activity in mouthwash.
13. UANL Autonomous University of Nuevo León. Antimicrobial sanitizing activity for direct use.
14. UANL Autonomous University of Nuevo León. Biodegradability of sanitizing agent for direct use.
15. Mother and Child Hospital in Guerrero. Certificate of sanitizing residuality for direct use.
16. ACCUGEN Laboratory, USA. 3rd FDA. Staphylococcus Aureus Test for the germicidal and detergent action of disinfectants.
17. ACCUGEN Laboratory, USA. 3rd FDA. Pseudomonas Aeruginosa Test for germicidal and detergent hygienic action of disinfectants.
18. ACCUGEN Laboratory, USA. 3rd FDA. Salmonella Enterica Test for germicidal and detergent hygienic action of disinfectants.
19. ACCUGEN Laboratories USA. 3rd FDA. Clostridium difficile and clostridium spores.
20. ACCUGEN Laboratories USA. 3rd FDA. In vitro Cytotoxicity: direct-use sanitizing agent.
21. ACCUGEN Laboratories USA. 3rd FDA. Corrosivity: direct-use sanitizing agent.
22. Faculty of Veterinary Medicine and Zootechnics. UNAM. Evaluation of direct-use sanitizing agent against Escherichia coli.
23. Microbiology Laboratory Pasteur, SA de CV. Microbial Challenge: direct-use sanitizing agent.
24. High Specialized Naval Hospital. Disinfection with direct-use sanitizing agent. In situ test.
25. Fray Antonio Alcalde Civil Hospital, Guadalajara, Mexico. Disinfection with direct-use sanitizing agent. In situ test.
26. Valentín Gómez Farías Hospital. Disinfection with direct-use sanitizing agent. In situ test.
27. ISSSTE. Western Regional Delegation. Disinfection with direct-use sanitizing agent. In situ test.
28. Study to determine the effectiveness of Éviter active nanoparticulate in two second-level hospitals.
29. General Hospital of Torreón, Coahuila. Éviter Effectiveness. Disinfection with direct-use sanitizing agent. In situ test.
30. UMAE H. Pediatrics C.M.N Siglo XXI. Éviter Effectiveness. Disinfection with direct-use sanitizing agent. In situ test.
31. Spanish Beneficence of La Laguna, Torreón Coahuila. Éviter Effectiveness. Disinfection with direct-use sanitizing agent. In situ test.
32. General Hospital of Acapulco. Disinfection with direct-use sanitizing agent. In situ test.
33. 20 de Noviembre Hospital. Disinfection with direct-use sanitizing agent. In situ test.
34. GEA González Hospital. Disinfection with direct-use sanitizing agent. In situ test.
35. Nicolás San Juan Hospital, State of Mexico. Disinfection with direct-use sanitizing agent. In situ test.
Leave a comment
This site is protected by hCaptcha and the hCaptcha Privacy Policy and Terms of Service apply.